Target intelligence / Profile preview

Cell-free chromatin particle (cfChP)

Target
cfChP
Molecular classification
Nucleoprotein complex, Damage-associated molecular pattern (DAMP), Chromatin
01

Overview

Cell-free chromatin particles (cfChPs) are fragments of DNA and histones released into the circulation and extracellular space during cell death via apoptosis or necrosis (Mittra et al., 2012, J. Biosci.). These particles act as damage-associated molecular patterns (DAMPs), capable of entering healthy cells to induce double-strand DNA breaks, genomic instability, and inflammatory cytokine production (Mittra et al., 2015, Ann. Oncol.). In oncology, cfChPs are implicated in the progression of metastasis and the development of therapy-related toxicities by damaging healthy tissue (Inderjit et al., 2021, Front. Genet.). In acute inflammatory states like sepsis and COVID-19, elevated levels of cfChPs contribute to the cytokine storm and multi-organ dysfunction (Raghuram et al., 2021, PLoS One). Therapeutic interventions aim to degrade these particles using DNase I or a combination of Resveratrol and Copper (R-Cu), which generates oxygen radicals to destroy the chromatin structure (Mittra et al., 2017, Free Radic. Biol. Med.). Such treatments have shown promise in reducing systemic inflammation and preventing cancer recurrence in preclinical models. Beyond cancer and sepsis, cfChPs are being investigated for their role in autoimmune diseases and diabetes-related complications (Pal et al., 2021, Sci. Rep.).

Other names
Extracellular DNACell-free DNAcfDNACirculating nucleosomeExtracellular fragmented DNAecDNACirculating chromatin
02

Mechanism of action

Enzymatic or oxidative degradation of extracellular DNA and histone components to neutralize their activity as damage-associated molecular patterns (DAMPs) and prevent their uptake by healthy cells.

03

Biological functions

Pro-inflammatory signalingInduction of genomic instabilityCell death inductionImmune activationHorizontal gene transfer
04

Disease associations

CancerSepsisSystemic inflammatory response syndromeAutoimmune diseaseCOVID-19Diabetes complications
05

Safety considerations

Rapid clearance of DNase enzymes from circulationPotential for systemic oxidative stress with metal catalystsInterference with neutrophil extracellular traps (NETs) required for pathogen entrapment
06

Interacting drugs

Dornase alfa (DNase I)

4 more in the full profile.

07

Biomarkers

Circulating cell-free DNA (cfDNA) levelsNucleosome concentrationCitrullinated histone H3 (H3Cit)

Beyond the preview

Go deeper on Cell-free chromatin particle (cfChP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell-free chromatin particle (cfChP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call